BDC-4182

BDC-4182 is a monoclonal antibody developed by Bolt Biotherapeutics. Its target is Claudin 18.2 (the sponsor names Claudin 18.2). The sponsor states: A 'Boltbody' immune-stimulating antibody conjugate (ISAC) combining an anti-Claudin 18.2 monoclonal antibody with a TLR7/8 dual agonist, working through immune activation (inducing immunological memory) rather than direct cytotoxicity. ClinicalTrials.gov describes the intervention as: Immune stimulating antibody conjugate (ISAC), consisting of an anti-claudin 18.2 monoclonal antibody conjugated to a TLR 7/8 dual agonist. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in gastric & gastro-oesophageal junction cancer. The largest, NCT06921837, plans to enrol 122 participants with primary completion expected 2027-05. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.